AR064494A1 - Variantes de lipasa para uso farmaceutico - Google Patents

Variantes de lipasa para uso farmaceutico

Info

Publication number
AR064494A1
AR064494A1 ARP070105859A ARP070105859A AR064494A1 AR 064494 A1 AR064494 A1 AR 064494A1 AR P070105859 A ARP070105859 A AR P070105859A AR P070105859 A ARP070105859 A AR P070105859A AR 064494 A1 AR064494 A1 AR 064494A1
Authority
AR
Argentina
Prior art keywords
lipases
lipase
pharmaceutical use
protease
diabetes
Prior art date
Application number
ARP070105859A
Other languages
English (en)
Spanish (es)
Original Assignee
Novozymes As
Novozymes Biotech Inc
Solvay Pharm Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novozymes As, Novozymes Biotech Inc, Solvay Pharm Gmbh filed Critical Novozymes As
Publication of AR064494A1 publication Critical patent/AR064494A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/18—Carboxylic ester hydrolases (3.1.1)
    • C12N9/20—Triglyceride splitting, e.g. by means of lipase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/54—Mixtures of enzymes or proenzymes covered by more than a single one of groups A61K38/44 - A61K38/46 or A61K38/51 - A61K38/53
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/01—Carboxylic ester hydrolases (3.1.1)
    • C12Y301/01003—Triacylglycerol lipase (3.1.1.3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Nutrition Science (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Detergent Compositions (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
ARP070105859A 2006-12-21 2007-12-21 Variantes de lipasa para uso farmaceutico AR064494A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US87119606P 2006-12-21 2006-12-21

Publications (1)

Publication Number Publication Date
AR064494A1 true AR064494A1 (es) 2009-04-08

Family

ID=38043020

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070105859A AR064494A1 (es) 2006-12-21 2007-12-21 Variantes de lipasa para uso farmaceutico

Country Status (16)

Country Link
US (3) US8273348B2 (enExample)
EP (6) EP2261328B1 (enExample)
JP (1) JP5406040B2 (enExample)
KR (1) KR20090101930A (enExample)
CN (2) CN105112386A (enExample)
AR (1) AR064494A1 (enExample)
AU (1) AU2007337150A1 (enExample)
BR (1) BRPI0721103A2 (enExample)
CA (3) CA3081308C (enExample)
IL (1) IL198893A0 (enExample)
MX (1) MX2009006597A (enExample)
NO (1) NO20092729L (enExample)
RU (1) RU2009128067A (enExample)
TW (1) TW200829698A (enExample)
WO (1) WO2008079685A2 (enExample)
ZA (1) ZA200903598B (enExample)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2314646T3 (es) 2004-03-22 2009-03-16 Solvay Pharmaceuticals Gmbh Composiciones farmaceuticas por via de productos que contienen lipasa , en particular de pancreatina, que contienen tensioactivos.
HUE031042T2 (en) 2005-07-29 2017-06-28 Abbott Laboratories Gmbh Methods for producing pancreatin powder with low viral content
US9198871B2 (en) 2005-08-15 2015-12-01 Abbott Products Gmbh Delayed release pancreatin compositions
US11266607B2 (en) 2005-08-15 2022-03-08 AbbVie Pharmaceuticals GmbH Process for the manufacture and use of pancreatin micropellet cores
US10072256B2 (en) 2006-05-22 2018-09-11 Abbott Products Gmbh Process for separating and determining the viral load in a pancreatin sample
US8273348B2 (en) * 2006-12-21 2012-09-25 Novozymes A/S Lipase variants for pharmaceutical use
BRPI0909707A2 (pt) * 2008-02-29 2015-08-25 Procter & Gamble Composição detergente que compreende lipase.
MX2010009464A (es) 2008-02-29 2010-09-22 Dsm Ip Assets Bv Lipasas con alta especificidad hacia acidos grasos de cadena corta y usos de las mismas.
CN101990573B (zh) * 2008-02-29 2014-01-22 诺维信公司 具有改进的稳定性的脂肪分解酶变体及编码该变体的多核苷酸
MX2012006616A (es) 2009-12-09 2012-06-21 Procter & Gamble Productos para el cuidado de las telas y el hogar.
DK2734633T3 (da) 2011-07-22 2019-06-11 Novozymes North America Inc Fremgangsmåder til forbehandling af celluloseholdigt materiale og forbedring af hydrolyse deraf
US8268305B1 (en) 2011-09-23 2012-09-18 Bio-Cat, Inc. Method and compositions to reduce serum levels of triacylglycerides in human beings using a fungal lipase
US9809787B2 (en) * 2011-12-29 2017-11-07 Novozymes A/S Detergent compositions comprising lipase
DK3211074T3 (da) * 2012-02-03 2020-06-02 Novozymes As Lipasevarianter og polynukleotider, som koder for dem
WO2013149858A1 (en) 2012-04-02 2013-10-10 Novozymes A/S Lipase variants and polynucleotides encoding same
CN110093330B (zh) * 2012-10-12 2023-11-28 丹尼斯科美国公司 包含脂解酶变体的组合物和方法
MY192746A (en) 2013-05-14 2022-09-06 Novozymes As Detergent compositions
EP3696264B1 (en) * 2013-07-19 2023-06-28 Danisco US Inc. Compositions and methods comprising a lipolytic enzyme variant
WO2016079305A1 (en) * 2014-11-20 2016-05-26 Novozymes A/S Alicyclobacillus variants and polynucleotides encoding same
US10457921B2 (en) 2014-12-05 2019-10-29 Novozymes A/S Lipase variants and polynucleotides encoding same
WO2016091870A1 (en) * 2014-12-09 2016-06-16 Novozymes A/S Lipase variants and polynucleotides encoding same
EP3280818A2 (en) 2015-04-07 2018-02-14 Novozymes A/S Methods for selecting enzymes having lipase activity
CA3175255A1 (en) * 2015-07-01 2017-01-05 Novozymes A/S Methods of reducing odor
US10760037B2 (en) * 2015-07-03 2020-09-01 Novozymes A/S Sulfite compositions
WO2018015295A1 (en) 2016-07-18 2018-01-25 Novozymes A/S Lipase variants, polynucleotides encoding same and the use thereof
EP3575398A4 (en) * 2017-01-30 2020-11-11 Nippon Medical School Foundation ADENO-ASSOCIATED VIRUS (AAV) CAPSIDE PROTEIN MUTANT
CA3072932C (en) 2017-09-27 2023-09-26 The Procter & Gamble Company Detergent compositions comprising lipases
CA3073362A1 (en) * 2017-09-27 2019-04-04 Novozymes A/S Lipase variants and microcapsule compositions comprising such lipase variants
CN111757930A (zh) * 2018-02-08 2020-10-09 诺维信公司 脂肪酶变体及其组合物
CA3109082A1 (en) * 2018-08-16 2020-02-20 Isolere Bio, Inc. Genetically encoded polypeptide for affinity capture and purification of biologics
CN111334369B (zh) * 2020-03-11 2022-10-21 陕西科技大学 一种酶法制备卵磷脂型pufa的方法
EP4172325A1 (en) * 2020-06-24 2023-05-03 Cilian AG New lipase enzyme
US20240035005A1 (en) * 2020-10-29 2024-02-01 Novozymes A/S Lipase variants and compositions comprising such lipase variants
CN113846074B (zh) * 2021-10-20 2022-10-21 南京林业大学 一种疏棉状嗜热丝孢菌脂肪酶突变体g91c及其应用
CN116732002A (zh) * 2022-03-01 2023-09-12 中国科学院天津工业生物技术研究所 一种耐受表面活性剂的脂肪酶变体及其应用
US20250311734A1 (en) 2022-05-14 2025-10-09 Novozymes A/S Compositions and Methods for Preventing, Treating, Suppressing and/or Eliminatting Phytopathogenic Infestations and Infections
US20250368924A1 (en) * 2022-06-24 2025-12-04 Novozymes A/S Lipase variants and compositions comprising such lipase variants
CN120082537B (zh) * 2023-12-01 2026-03-17 青岛蔚蓝生物集团有限公司 一种脂肪酶突变体
TWI903491B (zh) * 2024-05-09 2025-11-01 國立高雄科技大學 水體與沉積物通量培養系統

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK173590D0 (da) 1990-06-06 1990-07-19 Novo Nordisk As Rekombinante terapeutiske lipaser
US5869438A (en) 1990-09-13 1999-02-09 Novo Nordisk A/S Lipase variants
DK46693D0 (enExample) * 1993-04-23 1993-04-23 Novo Nordisk As
DK0548228T3 (da) * 1990-09-13 1999-05-10 Novo Nordisk As Lipasevarianter
CA2095852C (en) 1990-12-05 2001-05-08 Uffe Lovborg Proteins with changed epitopes and methods for the production thereof
JPH06507071A (ja) 1991-05-01 1994-08-11 ノボザイムス アクティーゼルスカブ 安定化酵素
DK39693D0 (da) 1993-04-02 1993-04-02 Novo Nordisk As Enzym
WO1995009909A1 (en) 1993-10-04 1995-04-13 Novo Nordisk A/S An enzyme preparation comprising a modified enzyme
MX9603542A (es) 1994-02-22 1997-03-29 Novo Nordisk As Metodo para preparar una variante de una enzima lipolitica.
AU3924095A (en) 1994-11-24 1996-06-17 Novo Nordisk A/S A process for producing polypeptides with reduced allergenicity
AU697440B2 (en) 1994-12-07 1998-10-08 Novozymes A/S Polypeptide with reduced allergenicity
EP0805856B2 (en) 1995-01-26 2009-04-01 Novozymes A/S Animal feed additives comprising xylanase
EP0839186B1 (en) 1995-07-14 2004-11-10 Novozymes A/S A modified enzyme with lipolytic activity
US6495357B1 (en) 1995-07-14 2002-12-17 Novozyme A/S Lipolytic enzymes
JP4068142B2 (ja) 1995-08-11 2008-03-26 ノボザイムス アクティーゼルスカブ 新規の脂肪分解酵素
JP2002510963A (ja) 1997-01-10 2002-04-09 ノボザイムス アクティーゼルスカブ スキンケア用酵素修飾体
JP2001511162A (ja) 1997-02-06 2001-08-07 ノボ ノルディスク アクティーゼルスカブ 付加され、そして／又は除去された付着基を有するポリペプチド−ポリマー結合体
WO1999000489A1 (en) 1997-06-25 1999-01-07 Novo Nordisk A/S A modified polypeptide
AU3247699A (en) 1998-02-17 1999-09-06 Novo Nordisk A/S Lipase variant
ATE328070T1 (de) * 1998-02-17 2006-06-15 Novozymes As Lipasevariante
CN1323345A (zh) 1998-10-13 2001-11-21 诺沃奇梅兹有限公司 具有降低的免疫应答的修饰多肽
JP2003500003A (ja) 1998-10-30 2003-01-07 ノボザイムス アクティーゼルスカブ 低いアレルゲン性のタンパク質変異型
ATE365210T1 (de) 1998-10-30 2007-07-15 Novozymes As Glykosylierte proteine mit reduzierter allergenität
US7312062B2 (en) * 1998-11-27 2007-12-25 Novozymes A/S Lipolytic enzyme variants
EP1131416B1 (en) 1998-11-27 2009-09-02 Novozymes A/S Lipolytic enzyme variants
EP1162995B1 (de) 1999-03-17 2003-06-04 Solvay Pharmaceuticals GmbH Enzyme zur behandlung von diabetes mellitus typ i
KR20010108379A (ko) * 1999-03-31 2001-12-07 피아 스타르 리파제 변이체
EP2278000A1 (en) * 1999-03-31 2011-01-26 Novozymes A/S Lipase variant
KR20020077421A (ko) 2000-02-08 2002-10-11 에프. 호프만-라 로슈 아게 동물 사료에서 산-안정성 서브틸리신 프로테아제의 사용
CA2406621A1 (en) * 2000-04-28 2001-11-08 Novozymes A/S Protein variants having modified immunogenicity
CA2431972C (en) * 2001-01-10 2012-10-23 Novozymes A/S Thermostable lipolytic enzyme variant
AR032392A1 (es) * 2001-01-19 2003-11-05 Solvay Pharm Gmbh Mezcla de enzimas, preparado farmaceutico y utilizacion de dicho preparado.
JP4287149B2 (ja) 2001-02-07 2009-07-01 ノボザイムス アクティーゼルスカブ リパーゼ変異体
DK2295556T3 (en) 2002-01-16 2015-01-26 Novozymes As Lipolytic Enzyme Variants and Method of Preparation thereof.
AU2004208860A1 (en) 2003-02-06 2004-08-19 Novozymes A/S Human heavy chain antibody expression in filamentous fungi
EP2290057A3 (en) 2003-05-09 2011-08-03 Novozymes A/S Variant lipolytic enzymes
US20060236414A1 (en) 2003-06-19 2006-10-19 Novozymes A/S Proteases and methods for producing them
US20060251763A1 (en) 2003-06-19 2006-11-09 Patkar Shamkant A Phospholipase variants
WO2005070962A1 (en) 2004-01-21 2005-08-04 Novozymes A/S Production of a monoclonal antibody in a heterokaryon fungus or in a fungal host cell
ES2314646T3 (es) 2004-03-22 2009-03-16 Solvay Pharmaceuticals Gmbh Composiciones farmaceuticas por via de productos que contienen lipasa , en particular de pancreatina, que contienen tensioactivos.
SI1809320T1 (sl) 2004-10-14 2010-11-30 Cystic Fibrosis Foundation Therapeutics Inc Sestavki ki vsebujejo lipazo proteazo in amilazo za zdravljenje pankreasne insuficience
EP1851311A2 (en) 2005-02-10 2007-11-07 Novozymes A/S Enzymatic enantioselective ester or amide hydrolysis or synthesis
AU2006261443A1 (en) 2005-06-24 2006-12-28 Novozymes A/S Proteases for pharmaceutical use
EP1896057A2 (en) 2005-06-24 2008-03-12 Novozymes A/S Amylases for pharmaceutical use
US20090047266A1 (en) * 2005-06-24 2009-02-19 Novozymes A/S Lipases for Pharmaceutical Use
WO2007080197A2 (en) * 2006-01-16 2007-07-19 Novozymes A/S Immobilised enzymes
ES2629332T3 (es) * 2006-01-23 2017-08-08 Novozymes A/S Variantes de lipasa
JP2009523900A (ja) 2006-01-23 2009-06-25 ザ プロクター アンド ギャンブル カンパニー リパーゼと漂白剤触媒を含む組成物
US8273348B2 (en) * 2006-12-21 2012-09-25 Novozymes A/S Lipase variants for pharmaceutical use

Also Published As

Publication number Publication date
EP2455459A2 (en) 2012-05-23
CA2670643A1 (en) 2008-07-03
AU2007337150A1 (en) 2008-07-03
EP2261328A1 (en) 2010-12-15
NO20092729L (no) 2009-09-18
US20120308543A1 (en) 2012-12-06
EP2099907A2 (en) 2009-09-16
TW200829698A (en) 2008-07-16
US9029115B2 (en) 2015-05-12
CN101743308B (zh) 2015-09-16
CN105112386A (zh) 2015-12-02
EP2261328B1 (en) 2013-11-20
JP5406040B2 (ja) 2014-02-05
EP2455462A3 (en) 2013-05-29
JP2010512795A (ja) 2010-04-30
KR20090101930A (ko) 2009-09-29
EP2455461A3 (en) 2013-05-29
CN101743308A (zh) 2010-06-16
WO2008079685A2 (en) 2008-07-03
US20100034797A1 (en) 2010-02-11
US9539311B2 (en) 2017-01-10
EP2455460A2 (en) 2012-05-23
US8273348B2 (en) 2012-09-25
CA3081308C (en) 2024-02-20
BRPI0721103A2 (pt) 2014-03-04
ZA200903598B (en) 2010-04-28
CA2961041C (en) 2020-07-14
EP2455459B1 (en) 2016-03-16
EP2455460A3 (en) 2012-12-26
EP2455459A3 (en) 2013-04-24
CA2961041A1 (en) 2008-07-03
CA3081308A1 (en) 2008-07-03
RU2009128067A (ru) 2011-01-27
CA2670643C (en) 2017-04-25
EP2455461A2 (en) 2012-05-23
IL198893A0 (en) 2010-02-17
MX2009006597A (es) 2009-07-02
EP2455461B1 (en) 2016-03-16
WO2008079685A3 (en) 2008-11-06
EP2455462A2 (en) 2012-05-23
EP2455462B1 (en) 2016-03-16
US20150209414A1 (en) 2015-07-30

Similar Documents

Publication Publication Date Title
AR053634A1 (es) Lipasas para uso farmaceutico
MX2009006597A (es) Variantes de lipasa para uso farmaceutico.
Ueda et al. N-acylethanolamine metabolism with special reference to N-acylethanolamine-hydrolyzing acid amidase (NAAA)
Li et al. Cordycepin inhibits LPS-induced inflammatory and matrix degradation in the intervertebral disc
ES2572160T3 (es) Una nueva preparación farmacéutica para preeclampsia
MX2007015471A (es) Amilasas para uso farmaceutico.
ATE473010T1 (de) Enzyme für pharmazeutische anwendung
AR032392A1 (es) Mezcla de enzimas, preparado farmaceutico y utilizacion de dicho preparado.
Paula et al. Modulation of the peroxiredoxin system by cytokines in insulin-producing RINm5F cells: down-regulation of PRDX6 increases susceptibility of beta cells to oxidative stress
ECSP088758A (es) Métodos para reducir la aglomeración de proteína
EP4413994A3 (en) Manufacture of active highly phosphorylated human lysosomal sulfatase enzymes and uses thereof
CL2017000498A1 (es) Una formulación de n-acetilgalactosamina-6-sulfatasa humana activa altamente fosforida (galns)(divisional solicitud 219-2013)
EP4241854A3 (en) Lysosomal storage disease enzyme
JP2010512795A5 (enExample)
WO2005111008A3 (en) Compounds for enzyme inhibition
AR063570A1 (es) Efectos biologicos mejorados para composiciones que comprenden acido rosmarinico
BR112012000914B8 (pt) uso de polipeptídeo com atividade condrogênica, método in vitro de indução da diferenciação de células-tronco mesenquimais em condrócitos, e composição farmacêutica para aplicação intra-articular
Bhatta et al. Angiotensin II-induced arterial thickening, fibrosis and stiffening involves elevated arginase function
CO6650415A2 (es) Nuevas formas de dosificacion de liberación modificada de un inhibidor de la xantina oxidorreductasa o de inhibidoes de xantina oxidasa
MX2015000760A (es) Sistema de suministro de farmaco gastro - retentivo.
AR071261A1 (es) Variantes de proteasa para uso farmaceutico
Gidlöf Toward a new paradigm for targeted natriuretic peptide enhancement in heart failure
Tafrova et al. Human histone acetyltransferase 1 (Hat1) acetylates lysine 5 of histone H2A in vivo
Xiao et al. The protein kinase C cascade regulates recruitment of matrix metalloprotease 9 to podosomes and its release and activation
AR078291A1 (es) Composiciones de enzimas pancreaticas y metodos para tratar pancreatitis e insuficiencia pancreatica

Legal Events

Date Code Title Description
FA Abandonment or withdrawal